Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBW
Period2019-01-01 → 2019-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100IBOW.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥1.3bn2019-01-01 → 2019-12-31StandaloneNet sales
Revenue¥169m2018-01-01 → 2018-12-31StandaloneNet sales
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Operating income−¥511m2019-01-01 → 2019-12-31StandaloneOperating income
Operating income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOperating income
Ordinary income−¥539m2019-01-01 → 2019-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥909m2019-01-01 → 2019-12-31StandaloneIncome before income taxes
Profit before tax−¥1.2bn2018-01-01 → 2018-12-31StandaloneIncome before income taxes
Net income−¥912m2019-01-01 → 2019-12-31StandaloneProfit loss
Net income−¥1.2bn2018-01-01 → 2018-12-31StandaloneProfit loss
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.4bnat 2019-12-31StandaloneAssets
Total assets¥3.4bnat 2018-12-31StandaloneAssets
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥926mat 2019-12-31StandaloneLiabilities
Total liabilities¥529mat 2018-12-31StandaloneLiabilities
Net assets / equity¥3.5bnat 2019-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.3bnat 2019-12-31StandaloneCash and deposits
Cash and deposits¥2.5bnat 2018-12-31StandaloneCash and deposits
Cash & equivalents¥3.1bnat 2019-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥238m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥4m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥342m2018-01-01 → 2018-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥240.71at 2019-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio78.7%at 2019-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued14,331,300at 2019-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees27at 2019-12-31StandaloneNumber of employees
Employees30at 2018-12-31StandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingdepreciation2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2019-12-31¥3.9bn
Reconciling Itemsreconcilingsegment profit2019-01-01 → 2019-12-31−¥733m
Diagnostic Divisionreportable segmentcapex2019-01-01 → 2019-12-31¥10m
Diagnostic Divisionreportable segmentdepreciation2019-01-01 → 2019-12-31¥303,000
Diagnostic Divisionreportable segmentemployeesat 2019-12-316 pure
Diagnostic Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentsegment assetsat 2019-12-31¥10m
Diagnostic Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31−¥152m
Pharmaceutical Divisionreportable segmentemployeesat 2019-12-317 pure
Pharmaceutical Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentsegment assetsat 2019-12-31¥420m
Pharmaceutical Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31¥373m
—segment totalemployeesat 2019-12-3113 pure
Total Of Reportable Segments And Otherssegment totalcapex2019-01-01 → 2019-12-31¥10m
Total Of Reportable Segments And Otherssegment totaldepreciation2019-01-01 → 2019-12-31¥303,000
Total Of Reportable Segments And Otherssegment totalrevenue2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2019-12-31¥430m
Total Of Reportable Segments And Otherssegment totalsegment profit2019-01-01 → 2019-12-31¥221m
Reconciling Itemsreconcilingdepreciation2018-01-01 → 2018-12-31¥2m
Reconciling Itemsreconcilingsegment profit2018-01-01 → 2018-12-31−¥593m
Diagnostic Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥170m
Pharmaceutical Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥485m
Total Of Reportable Segments And Otherssegment totalrevenue2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2018-01-01 → 2018-12-31−¥654m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 897
ItemContextValueUnit
Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting companyPrior1YearInstant_Row1Member266270
Book value details of specified investment equity securities held for purposes other than pure investment reporting companyCurrentYearInstant_Row1Member713000JPY
Book value details of specified investment equity securities held for purposes other than pure investment reporting companyPrior1YearInstant_Row1Member2081000JPY
Cash and depositsPrior1YearInstant_NonConsolidatedMember2463138000JPY
Cash and depositsCurrentYearInstant_NonConsolidatedMember3342585000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember50063000JPY
Accounts receivable tradeCurrentYearInstant_NonConsolidatedMember169308000JPY
Finished goodsPrior1YearInstant_NonConsolidatedMember9121000JPY
Finished goodsCurrentYearInstant_NonConsolidatedMember8504000JPY
Work in processPrior1YearInstant_NonConsolidatedMember－JPY
Work in processCurrentYearInstant_NonConsolidatedMember3898000JPY
SuppliesPrior1YearInstant_NonConsolidatedMember1941000JPY
SuppliesCurrentYearInstant_NonConsolidatedMember2515000JPY
Advance payments otherPrior1YearInstant_NonConsolidatedMember4084000JPY
Advance payments otherCurrentYearInstant_NonConsolidatedMember47737000JPY
Prepaid expensesPrior1YearInstant_NonConsolidatedMember29438000JPY
Prepaid expensesCurrentYearInstant_NonConsolidatedMember202709000JPY
Short term loans receivable to subsidiaries and affiliatesPrior1YearInstant_NonConsolidatedMember－JPY
Short term loans receivable to subsidiaries and affiliatesCurrentYearInstant_NonConsolidatedMember10954000JPY
Accounts receivable otherPrior1YearInstant_NonConsolidatedMember27843000JPY
Accounts receivable otherCurrentYearInstant_NonConsolidatedMember37069000JPY
Consumption taxes receivablePrior1YearInstant_NonConsolidatedMember31755000JPY
Consumption taxes receivableCurrentYearInstant_NonConsolidatedMember－JPY
Other caPrior1YearInstant_NonConsolidatedMember726000JPY
Other caCurrentYearInstant_NonConsolidatedMember1146000JPY
Current assetsPrior1YearInstant_NonConsolidatedMember2618115000JPY
Current assetsCurrentYearInstant_NonConsolidatedMember3826429000JPY
BuildingsPrior1YearInstant_NonConsolidatedMember2794000JPY
BuildingsCurrentYearInstant_NonConsolidatedMember2794000JPY
Accumulated depreciation buildingsPrior1YearInstant_NonConsolidatedMember-2794000JPY
Accumulated depreciation buildingsCurrentYearInstant_NonConsolidatedMember-2794000JPY
Buildings netPrior1YearInstant_NonConsolidatedMember－JPY
Buildings netCurrentYearInstant_NonConsolidatedMember－JPY
Tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember68772000JPY
Tools furniture and fixturesCurrentYearInstant_NonConsolidatedMember73673000JPY
Accumulated depreciation tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember-66516000JPY
Accumulated depreciation tools furniture and fixturesCurrentYearInstant_NonConsolidatedMember-61849000JPY
Tools furniture and fixtures netPrior1YearInstant_NonConsolidatedMember2256000JPY
Tools furniture and fixtures netCurrentYearInstant_NonConsolidatedMember11823000JPY
Property plant and equipmentPrior1YearInstant_NonConsolidatedMember2256000JPY
Property plant and equipmentCurrentYearInstant_NonConsolidatedMember11823000JPY
SoftwarePrior1YearInstant_NonConsolidatedMember－JPY
SoftwareCurrentYearInstant_NonConsolidatedMember850000JPY
Intangible assetsPrior1YearInstant_NonConsolidatedMember－JPY
Intangible assetsCurrentYearInstant_NonConsolidatedMember850000JPY
Investment securitiesPrior1YearInstant_NonConsolidatedMember668201000JPY
Investment securitiesCurrentYearInstant_NonConsolidatedMember329333000JPY
Stocks of subsidiaries and affiliatesPrior1YearInstant_NonConsolidatedMember101153000JPY
Stocks of subsidiaries and affiliatesCurrentYearInstant_NonConsolidatedMember101153000JPY
Investments in capitalPrior1YearInstant_NonConsolidatedMember100000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2018-12-31pass
balance sheet identitynon_consolidated 2019-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · operating cash flownon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · operating cash flownon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · revenuenon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · revenuenon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · total assetsnon_consolidated 2018-12-31pass
statement vs summary · total assetsnon_consolidated 2019-12-31pass